Diabetes and cardiovascular risk markers

Current Medical Research and Opinion, Supplement

Volumn 21, Issue 1, 2005, Pages

  Erdmann, E ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Cardiovascular disease; Dyslipidaemia; Insulin resistance; Metabolic syndrome; Thiazolidinedione; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLICLAZIDE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PRAVASTATIN; ROSIGLITAZONE; SIMVASTATIN; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE MARKER; DRUG POTENTIATION; DYSLIPIDEMIA; HUMAN; INFLAMMATION; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW;

BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN RESISTANCE; PPAR GAMMA; RISK; THIAZOLIDINEDIONES;

EID: 16844365052     PISSN: 01419951     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X36459     Document Type: Review

References (95)

1. Geiss LS, Herman WH, Smith PJ. Mortality in non-insulin-dependent diabetes. In: Diabetes in America, 2nd edn. National Diabetes Data Group, National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases. NIH Publication No. 95-1468, 1995, pp.233-57
2. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001;44:S14-21
3. Lee ET, Keen H, Bennett PH, Fuller JH, Lu M. Follow-up of the WHO Multinational Study of Vascular Disease in Diabetes: general description and morbidity. Diabetologia 2001;44(Suppl. 2):S3-13
4. Caro JJ, Ward AJ, O'Brien JA. Lifetime costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care 2002;25:476-81
5. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34
6. Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987;3:463-524
7. de Vegt F, Dekker JM, Ruhé HG, et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999;42:926-31
8. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation 1979;59:8-13
9. Wingard DL, Barrett-Connor E. Heart Disease and Diabetes. In: Diabetes in America, 2nd edn. National Diabetes Data Group, National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases. NIH Publication No. 95-1468, 1995, pp.429-448
10. Mukamal KJ, Nesto RW, Cohen MC, et al. Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction. Diabetes Care 2001;24:1422-7
11. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
12. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC Jr, Sowers JR. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999;100:1134-46
13. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Geneva, World Health Organization, 1999
14. Laakso M. Insulin resistance and cardiovascular disease. Br J Diabetes Vasc Dis 2002;2:S9-II
15. Kendall DM, Sobel BE, Coulston AM, et al. The insulin resistance syndrome and coronary artery disease. Coron Artery Dis 2003;14:335-48
16. Klein R, Sharrett AR, Klein BE, et al., for the ARIC Group. The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: the atherosclerosis risk in communities study. Ophthalmology 2002;109:1225-34
17. Mykkanen L, Kuusisto J, Pyörälä K, Laakso M. Cardiovascular disease risk factors as predictors of type 2 (non-insulin- dependent) diabetes mellitus in elderly subjects. Diabetologia 1993;36:553-9
18. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9
19. Lakka H-M, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16
20. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9
21. Muntner P, He J, Chen J, Fonseca V, Whelton PK. Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol 2004;14:686-95
22. Berthezène F. Diabetic dyslipidaemia. Br J Diabetes Vasc Dis 2002;2:S12-7
23. Reaven GM. Insulin resistance: how important is it to treat? Exp Clin Endocrinol Diabetes 2000;108:S274-80
24. Bays H. Atherogenic dyslipidaemia in type 2 diabetes and metabolic syndrome: current and future treatment options. Br J Diabetes Vasc Dis 2003;3:356-60
25. Brunzell JD, Ayyobi AF. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med 2003;115:24S-8
26. Fonseca VA. Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease. Am J Cardiol 2003;92:50J-60
27. Turner RC, Milks H, Neil HAW, et al., for the United Kingdom Prospective Diabetes Study Group. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ 1998;316:823-8
28. Fontbonne A, Eschwege E, Cambien F, et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989;32:300-4
29. Hanefeld M, Fischer S, Julius U, et al., for the DIS Group. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577-83
30. Hsueh WA, Quiñones MJ. Role of endothelial dysfunction in insulin resistance. Am J Cardiol 2003;92:I0J-7
31. Hsueh WA, Lyon CJ, Quiñones MJ. Insulin resistance and the endothelium. Am J Med 2004;117:109-17
32. Mäkimattila S, Yki-Järvinen H. Endothelial dysfunction in human diabetes. Curr Diab Rep 2002;2:26-36
33. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004;27:813-23
34. Hsueh WA, Bruemmer D. Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease. Hypertension 2004;43:297-305 [Epub 19 Jan 2004]
35. Einhorn D, Aroda VR, Henry RR. Glitazones and the management of insulin resistance: what they do and how might they be used. Endocrinol Metab Clin North Am 2004;33:595-616,vii-viii
36. Haffner SM. Pre-diabetes, insulin resistance, inflammation and CVD risk. Diabetes Res Clin Pract 2003;61:S9-18
37. Nesto R. C-reactive protein, its role in inflammation, type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones. Diabet Med 2004;21:810-7
38. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996;144:537-47
39. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9
40. Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 1995;44:1303-9
41. Guerci B, Bohme P, Kearney-Schwartz A, Zannad F, Drouin P. Endothelial dysfunction and type 2 diabetes. Part 2: altered endothelial function and the effects of treatments in type 2 diabetes mellitus. Diabetes Metab 2001;27:436-47
42. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
43. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
44. Shin JJ, Rothman J, Farag A, McFarlane SI, Sowers JR. Role of oral anti-diabetic agents in modifying cardiovascular risk factors. Minerva Med 2003;94:401-8
45. Neve BP, Corseaux D, Chinetti G, et al. PPARα agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation 2001;103:207-12
46. Hsueh WA, Law RE. PPARγ and atherosclerosis: effects on cell growth and movement. Arterioscler Thromb Vasc Biol 2001;21:1891-5
47. Edelman SV. The role of the thiazolidinediones in the practical management of patients with type 2 diabetes and cardiovascular risk factors. Rev Cardiovasc Med 2003;4:S29-37
48. Florkowski CM. Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones. Am J Cardiovasc Drugs 2002;2:15-21
49. Gilling L, Suwattee P, DeSouza C, Asnani S, Fonseca V. Effects of the thiazolidinediones on cardiovascular risk factors. Am J Cardiovasc Drugs 2002;2:149-56
50. Greenberg AS. The expanding scope of the metabolic syndrome and implications for the management of cardiovascular risk in type 2 diabetes with particular focus on the emerging role of the thiazolidinediones. J Diabetes Complications 2003;17:218-28
51. Stolar MW, Chilton RJ. Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. Clin Ther 2003;25:B4-31
52. Zimmet P. Addressing the insulin resistance syndrome: a role for the thiazolidinediones. Trends Cardiovasc Med 2002;12:354-62
53. Meriden T. Progress with thiazolidinediones in the management of type 2 diabetes mellitus. Clin Ther 2004;26:177-90
54. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001;134:61-71
55. Smith U. Thiazolidinedione-induced effects beyond glycaemic control. Br J Diabetes Vasc Dis 2002;2:S24-7
56. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000;23:1605-11
57. Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med 2005;In Press. [EPub: 27 Oct 2004]
58. Derosa G, Cicero AFG, Gaddi A, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 2004;26:744-54
59. Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with Type 2 diabetes. Diabetes Care 2004;27:141-7
60. Herz M, Johns D, Reviriego J, et al., for the GLAB study group. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naïve patients with type 2 diabetes mellitus. Clin Ther 2003;25:1074-95
61. Khan MA, St. Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002;25:708-11
62. Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metabol Res Rev 2005;In Press. [EPub: 15 Jun 2004]
63. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001;24:710-19
64. Peters Harmel AL, Kendall DM, Buse JB, Boyle PJ, Marchetti A, Lau H. Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes. Curr Med Res Opin 2004;20:215-23
65. Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE and the Pioglitazone 026 Study Group. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001;12:413-23
66. Schernthaner G, Matthews D, Charbonnel B, Hanefeld M, Brunetti P. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004;89:6068-76
67. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000;22:1395-409
68. Perez A, Khan M, Johnson T, Karunaratne M. Effects of pioglitazone on lipid subspecies and subparticle profiles: results from a double-blind, randomized study of pioglitazone HCl vs placebo in reducing or eliminating insulin requirement in subjects with type 2 diabetes. Diabetes 2004;52:A141
69. Winkler K, Freedrich I, Baumstark MW, Wieland H, März W. Pioglitazone reduces atherogenic dense low density lipoprotein (LDL) particles in patients with type 2 diabetes mellitus. Br J Diabetes Vasc Dis 2002;2:143-8
70. Boyle PJ, Bennett King A, Olansky L, et al. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: A retrospective review of randomly selected medical records. Clin Ther 2002;24:378-96
71. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycaemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Late-breaking presentation at the American Heart Association, 2004
72. Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 2003;17:7-12
73. Rajagopalan R, Khan M. Effect of pioglitazone on metabolic syndrome risk markers in patients with type 2 diabetes: analysis from four randomized trials. Diabetes 2004;52:A142-3
74. Füllert S, Schneider F, Haak E, et al. Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 2002;87:5503-6
75. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on non-traditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679-84
76. Satoh N, Ogawa Y, Usui T, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003;26:2493-9
77. Pampanelli S, Rinaldi T, Perriello G, Brunetti P. Effects of pioglitazone on coagulation and thrombosis in comparison to gliclazide in patients with type 2 diabetes. Diabetes 2004;52:A140
78. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001;86:3452-6
79. American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care 2004;27:S68-71
80. Durrington P. Clinical trials of lipid-lowering medication in diabetes. Br J Diabetes Vasc Dis 2003;3:217-20
81. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
82. Sacks FM, Tonkin AM, Shepherd J, et al., for the Prospective Pravastatin Pooling Project Investigators Group. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 2000;102:1893-900
83. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, on behalf of the CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96
84. Snow V, Aronson MD, Hornbake ER, Mottur-Pilson C, Weiss KB; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2004;140:644-9
85. Vijan S, Hayward RA, American College of Physicians. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med 2004;140:650-8
86. Garg A. Statins for all patients with type 2 diabetes: not too soon. Lancet 2004;364:641-2
87. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998;98:2513-9
88. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16
89. Laakso M, Lehto S, Penttilä I, Pyörälä K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 1998;88:1421-30
90. Pyörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-20
91. Tack CJJ, Smits P, Demacker PNM, Stalenhoef AFH. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care 1998;21:796-9
92. Winkler K, Konrad T, Füllert S, et al. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension. A double-blind, placebo-controlled study. Diabetes Care 2003;26:2588-94
93. Lewin AJ, Kipnes MS, Meneghini LF, et al., for the Simvastatin/ Thiazolidinedione Study Group. Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 2004;26:379-89
94. Tan SA, Tan LG. Synergistic effects of simvastatin and pioglitazone on inflammatory cytokines interferon-gamma, tumor necrosis factor-alpha, interleukin-6 and C-reactive protein in diabetic patients with hyperlipidemia and coronary artery disease [AACE 2004 Abstract]. Endocr Pract 2004;10(Suppl. 1):21 [Abstract 58]
95. Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A. The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive): Can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 2004;27:1647-53